Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C

Antivir Ther. 2007;12(5):779-87.

Abstract

Introduction: Cell death during antiviral therapy of patients with chronic hepatitis C is not well understood.

Methods: In the present study, apoptotic activity was monitored by quantification of apoptotic cytokeratin-18 neoepitopes in serum from patients with chronic hepatitis C before and 4, 12, 24 and 48 weeks after initiation of antiviral therapy with pegylated interferon-alpha2a and ribavirin and was compared with viral kinetic parameters.

Results: After 4 weeks of treatment apoptotic activity decreased significantly compared with baseline. Later during treatment, however, apoptotic activity increased again to levels similar to baseline. Alanine aminotransferase (ALT) activity also showed a significant decrease at week 4 compared with baseline but, in contrast to apoptotic activity, ALT remained at a reduced level during the treatment period. Baseline apoptotic activity was inversely correlated with the infected cell loss while an increase of apoptotic activity within the first 4 treatment weeks compared with baseline was positively correlated with the infected cell loss.

Conclusions: Apoptosis appears to be an important form of cell death during interferon-alpha-based treatment and is associated with infected cell loss and underestimated by ALT activity.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Apoptosis / drug effects*
  • Case-Control Studies
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / enzymology
  • Hepatitis C, Chronic / pathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Keratin-18 / blood
  • Kinetics
  • Liver / drug effects*
  • Liver / enzymology
  • Liver / pathology
  • Liver / virology
  • Male
  • Middle Aged
  • Polyethylene Glycols / pharmacology
  • Polyethylene Glycols / therapeutic use*
  • Prospective Studies
  • Recombinant Proteins
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use*
  • Treatment Outcome
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • KRT18 protein, human
  • Keratin-18
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Alanine Transaminase
  • peginterferon alfa-2a